ASCO 2025: Developments in Gynecologic Oncology
 |
| Updates in Gynecologic Cancers From ASCO 2025 Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new treatment for patients with platinum-resistant ovarian cancer. Read More |
| IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data for IMNN-001 in advanced ovarian cancer. Read More |